1. Home
  2. LBGJ vs IRD Comparison

LBGJ vs IRD Comparison

Compare LBGJ & IRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LBGJ
  • IRD
  • Stock Information
  • Founded
  • LBGJ 2007
  • IRD 2018
  • Country
  • LBGJ China
  • IRD United States
  • Employees
  • LBGJ N/A
  • IRD N/A
  • Industry
  • LBGJ
  • IRD
  • Sector
  • LBGJ
  • IRD
  • Exchange
  • LBGJ NYSE
  • IRD NYSE
  • Market Cap
  • LBGJ 24.7M
  • IRD 59.1M
  • IPO Year
  • LBGJ 2024
  • IRD N/A
  • Fundamental
  • Price
  • LBGJ $1.25
  • IRD $1.13
  • Analyst Decision
  • LBGJ
  • IRD Strong Buy
  • Analyst Count
  • LBGJ 0
  • IRD 3
  • Target Price
  • LBGJ N/A
  • IRD $6.33
  • AVG Volume (30 Days)
  • LBGJ 10.1K
  • IRD 752.8K
  • Earning Date
  • LBGJ 08-15-2025
  • IRD 08-15-2025
  • Dividend Yield
  • LBGJ N/A
  • IRD N/A
  • EPS Growth
  • LBGJ N/A
  • IRD N/A
  • EPS
  • LBGJ N/A
  • IRD N/A
  • Revenue
  • LBGJ $11,781,015.00
  • IRD $13,651,000.00
  • Revenue This Year
  • LBGJ N/A
  • IRD $51.41
  • Revenue Next Year
  • LBGJ N/A
  • IRD $68.84
  • P/E Ratio
  • LBGJ N/A
  • IRD N/A
  • Revenue Growth
  • LBGJ 21.82
  • IRD N/A
  • 52 Week Low
  • LBGJ $1.02
  • IRD $0.65
  • 52 Week High
  • LBGJ $5.50
  • IRD $2.18
  • Technical
  • Relative Strength Index (RSI)
  • LBGJ N/A
  • IRD N/A
  • Support Level
  • LBGJ N/A
  • IRD N/A
  • Resistance Level
  • LBGJ N/A
  • IRD N/A
  • Average True Range (ATR)
  • LBGJ 0.00
  • IRD 0.00
  • MACD
  • LBGJ 0.00
  • IRD 0.00
  • Stochastic Oscillator
  • LBGJ 0.00
  • IRD 0.00

About LBGJ LI BANG INTERNATIONAL CORPORATION I

Li Bang International Corp Inc is a holding company. The firm through its subsidiaries engages in designing, developing, producing, and selling stainless steel commercial kitchen equipment in China under its own Libang brand. In addition, its subsidiaries provide customers with comprehensive services, from commercial kitchen design in the early stage to equipment installation and after-sales maintenance.

About IRD OPUS GENETICS INC

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.

Share on Social Networks: